BiotechTube

Ramucirumab + Somatostatin Analog

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Carcinoid Tumors

Conditions

Carcinoid Tumors

Trial Timeline

Jun 14, 2016 → Dec 31, 2023

NCT ID
NCT02795858

About Ramucirumab + Somatostatin Analog

Ramucirumab + Somatostatin Analog is a phase 2 stage product being developed by Eli Lilly for Carcinoid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT02795858. Target conditions include Carcinoid Tumors.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02795858Phase 2Completed

Competing Products

20 competing products in Carcinoid Tumors

See all competitors
ProductCompanyStageHype Score
PasireotideNovartisPhase 1
33
Pasireotide + OctreotideNovartisPhase 3
77
Pasireotide (SOM230)NovartisPhase 2
52
Octreotide + Placebo + EverolimusNovartisPhase 3
77
LutatheraNovartisPhase 2
52
EPO906 epothilone BNovartisPhase 2
52
PanitumumabAmgenPhase 2
51
AxitinibPfizerPhase 2
51
Lanreotide + Placebo (for sunitinib) + SunitinibPfizerPhase 2
51
Nivolumab + CabozantinibBristol Myers SquibbPhase 2
51
bevacizumab + 5-fluorouracil + leucovorin + oxaliplatinSanofiPhase 2/3
64
lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)IpsenPhase 3
74
lanreotide (Autogel formulation)IpsenApproved
82
Lanreotide + PlaceboIpsenPhase 3
74
BIM 23A760IpsenPhase 2
49
Randomized: 40 mg Paltusotine + Randomized: 80 mg PaltusotineCrinetics PharmaceuticalsPhase 2
47
Paltusotine + PlaceboCrinetics PharmaceuticalsPhase 3
72
Telotristat etiprate + Placebo-matching telotristat etiprateLexicon PharmaceuticalsPhase 3
72
Telotristat etiprateLexicon PharmaceuticalsPhase 3
72
500 mg [14C]-LX1606Lexicon PharmaceuticalsPhase 1
28

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85